泮托拉唑与雷贝拉唑治疗幽门螺杆菌感染活动性胃溃疡成本—效果对比观察

Cost-effectiveness comparison of pantoprazole and rabeprazole in the treatment of Helicobacter pylori infection with active gastric ulcer

目的对比泮托拉唑与雷贝拉唑治疗幽门螺杆菌(Hp)感染活动性胃溃疡成本—效果分析。方法抽取医院2015年11月-2016年11月收治的Hp感染活动期胃溃疡患者89例作为研究对象,随机分为泮托拉唑组(45例)和雷贝拉唑组(44例),比较2组患者的临床效果及花费成本。结果总有效率泮托拉唑组为97.78%,雷贝拉唑组为97.73%,2组比较差异无统计学意义(P>0.05);泮托拉唑组花费成本显著低于雷贝拉唑组,差异有统计学意义(P<0.05)。结论泮托拉唑和雷贝拉唑作为经典质子泵抑制剂治疗Hp感染活动性胃溃疡效果显著,但泮托拉唑更具药物经济学价值。

Objective To Compare the cost-effectiveness of pantoprazole and rabeprazole in the treatment of Helicobacter pylori（Hp） infection with active gastric ulcer.Methods 89 cases of gastric ulcer patients with Hp infection,collected from November 2015 to November 2016 in the hospital,were randomly divided into pantoprazole group（45 cases） and rabeprazole group（44 cases）.Compared the clinical efficacy and cost of two groups.Results The total effective rate of pantoprazole group was 97.78%,and the total effective rate of rabeprazole group was 97.73%,there was no significant difference in the total effective rate between two groups（P〉0.05）.The cost of donazazole group was significantly lower than that of rabeprazole group,the difference was statistically significant（P〈0.05）.Conclusion Pantoprazole and rabeprazole as classic proton pump inhibitor in the treatment of gastric ulcer caused by Hp infection have significant effect,but pantoprazole more drug economic value.